Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.

MLA

Sechi, Elia, et al. “Neurologic Autoimmunity and Immune Checkpoint Inhibitors: Autoantibody Profiles and Outcomes.” Neurology, vol. 95, no. 17, Oct. 2020, pp. e2442–52. EBSCOhost, https://doi.org/10.1212/WNL.0000000000010632.

APA

Sechi, E., Markovic, S. N., McKeon, A., Dubey, D., Liewluck, T., Lennon, V. A., Lopez-Chiriboga, A. S., Klein, C. J., Mauermann, M., Pittock, S. J., Flanagan, E. P., & Zekeridou, A. (2020). Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. Neurology, 95(17), e2442–e2452. https://doi.org/10.1212/WNL.0000000000010632

Chicago

Sechi, Elia, Svetomir N Markovic, Andrew McKeon, Divyanshu Dubey, Teerin Liewluck, Vanda A Lennon, A Sebastian Lopez-Chiriboga, et al. 2020. “Neurologic Autoimmunity and Immune Checkpoint Inhibitors: Autoantibody Profiles and Outcomes.” Neurology 95 (17): e2442–52. doi:10.1212/WNL.0000000000010632.